All News

An expert offers insight into the major treatment improvements over the past 20 years for early-stage and late-stage lung cancer.

There are ways to manage the fear of cancer recurrence, so it doesn’t become overwhelming or debilitating. Physicians like me and a network of resources are here to help.

Here are some tips on how I helped a friend who was recently diagnosed with breast cancer.

After a metastatic prostate cancer diagnosis, Robert Hollander decided to bring together his love of wine and his journey with cancer to create a foundation to support the research field.

Watch Dr. Aaron S. Mansfield, from Mayo Clinic, discuss the management of mesothelioma during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. David Gerber, from UT Southwestern Medical Center, discuss antibody drug conjugates during the CURE Educated Patient Lung Cancer Summit.

I’ve had leukemia for 13 years, and don’t owe anyone an explanation why my hair is short, or my face looks puffy.

Watch Dr. Hossein Borghaei, Dr. Jared Weiss and Dr. Anne Chiang answer questions about early disease management during the CURE Educated Patient Lung Cancer Summit.

Investigators of an expanded clinical trial have administered an investigational CAR-T cell therapy to the first patient with blood cancer.

I sent all my cancer scans to my pediatrician, who combined the power of science with the power of belief and helped me through the difficult time.

From Kevin Durant’s sneaker that is raising money for cancer to Khloe Kardashian’s urging people to check for moles and melanoma, here’s what’s happening in the cancer space this week.

Watch Dr. Anne Chiang, from Yale School of Medicine, discuss molecular testing and adjuvant targeted therapies during the CURE Educated Patient Lung Cancer Summit.

The CAR T Together initiative is geared toward improving the development of allogeneic CAR-T cell therapies for patients with cancer.

As PSA testing recommendations change and the debate surrounding testing continues, people with a high-risk of prostate cancer and their families need to stay informed.

I recently decided to stop feeling like a victim in life after cancer. Instead, I’ll celebrate life every day.

A woman with stage 2 invasive ductal carcinoma — a type of breast cancer that begins in the milk ducts of the breast — shares how her experience as an employee at a breast cancer research facility helped her push against doctors who minimized her ultrasound findings and how her Ki-67 score informed her treatment choices.

Watch Dr. Jared Weiss, from UNC School of Medicine, discuss neoadjuvant versus adjuvant therapy during the CURE Educated Patient Lung Cancer Summit.

Historically, there has been limited evidence to suggest the appropriate treatment sequencing of this melanoma patient population. However, new findings demonstrate starting with Opdivo plus Yervoy followed by Tafinlar in combination with Mekinist may be the best option.

In this poem, I chronicle "Suzy Q's" experience with acute lymphoblastic leukemia.

“Novel approaches to immunotherapy, targeted therapy and combinations with standard chemotherapy are all areas of current research interest,” says an expert at Dana-Farber Cancer Institute Sarcoma Center in Boston. “(Secondary breast cancer) can be very challenging when it recurs, so we need to continue to work toward improving systemic therapies through ongoing international trials and collaboration across the community of patients and physicians. That’s what’s going to help us improve outcomes.”

A professional illustrator and former cancer caregiver uses a detailed step-by-step approach using simple shapes such as circles and rectangles to demonstrate how others can easily draw a lion.

Twenty years of FDA approvals for the treatment of metastatic kidney cancer have allowed patients to live longer.

The Food and Drug Administration granted a priority review to Trodelvy for previously treated locally advanced or metastatic HR-positive, HER2-negative breast cancer.

NC410 plus Keytruda will be studied in a phase 1b/2 trial for patients with certain solid cancers that either did not respond to or have not been treated with an immunotherapy agent.

The designation of HER2-low status is rapidly reshaping how researchers and care providers not only think about, but also treat, breast cancer.

I wish “Pinktober” was more about saving the people who will die from breast cancer and less about pink ribbons and sexualizing the disease.

“I believe the key for many is to turn prostate cancer from a lethal disease to a chronic disease. That’s what we’re trying to do,” says an expert at the University of California, San Francisco.

Ten years after my brain cancer diagnosis, I feel hopeful and content with my life.